Published on
January 22, 2025
- 14:00 GMT
Vyome Therapeutics Presents Positive Data from Early Analysis of a Phase 2 Study of VT-1953 in Malignant Fungating Wound
VT-1953 significantly improves primary end point and quality of life of patients CAMBRIDGE, MA, UNITED STATES, January 22, 2025 /EINPresswire.com/ -- • VT-1953 treatment reduces malignant fungating wound-associated malodor over a 14 day period as …
Distribution channels:
Banking, Finance & Investment Industry, Chemical Industry
...
